1

Forward Looking Statements

Various statements we make in this presentation concerning our future expectations, plans and prospects, including, without limitation, statements related to our strategy, development plans, and our product and business goals, including statements relating to our plans to introduce our AUGMENT access program to at least four regions and achieve at least 40 AUGMENT cycles in 2014, achieve initial AUGMENT revenue in 2014, launch OvaPrime in 2015 and demonstrate preclinical human proof of concept for OvaTure by the end of 2014, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: our expectations regarding the potential regulatory path required for AUGMENTSM and OvaPrimeSM

outside of the United States; the science underlying our product candidates, which is unproven and may never lead to marketable products; our ability to obtain, maintain and protect intellectual property utilized by our products; our ability to obtain additional funding to support our business activities; our dependence on third parties for development (such as Intrexon), manufacture, marketing, sales and distribution of products; the successful development of our product candidates on the timelines we expect; obtaining necessary regulatory approvals for our product candidates; our ability to commercialize our product candidates, including AUGMENTSM and OvaPrimeSM, on the timelines we expect, if at all; competition from others developing products for similar uses; and our short operating history; as well as those risks more fully discussed in the “Risk Factors” section of our most recent 10-K and 10-Q and other reports on file with the Securities and Exchange Commission. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any

subsequent date. We do not assume any obligation to update any forward-looking statement.

2

• 90% of Market is International

Standard in vitro fertilization (IVF) fails ~70%

Mainly self pay

• Near-Term Product Launches

First launch underway

Second launch planned in 2015

• Proven Leadership

Scientific, clinical and commercial success

• Proprietary Platform

Growing patient portfolio for EggPCSM

technology

OvaScience: Developing New Fertility Treatments

3

U.S.

Rest of World

IVF Cycles

• EggPCs can be matured into young, healthy eggs

• Women are NOT born with a set number of eggs

Groundbreaking Discovery Enables New Fertility Treatments for Women

4

EggPCSM Technology Offers Suite of Products

AUGMENTSM

Proprietary EggPC Technology Platform

EggPCSM

OvaPrimeSM

Add Energy to Eggs

2014 launch

Boost Egg Reserve

2015 launch

Next Generation IVF; no hormone injections

OvaTureSM

5

Major Innovations First Discovered & Used Internationally

6 For IVF, Frozen Embryo, PGD, ICSI, and IVA: dates above indicate first baby born.

1978 2013 1984 1990 1992 2009

IVF Embryo Freezing PGD ICSI

Embryo Imaging IVA

1981

1993 2011

U.K. Australia U.K. Belgium Denmark Japan

IVF: In Vitro Fertilization

PGD: Pre-implantation Genetic Diagnostics

ICSI: Intracytoplasmic Sperm Injection

IVA: In Vitro Activation

1986 1992

* Middle East includes: Bahrain, Egypt, Jordan, Lebanon, Libya, Saudi Arabia, Syria, Tunisia, UAE, Israel Source: SART; ESHRE; ICMART; Country Registries; Latin America Registry; Israeli Ministry

Region Cycles

Japan* 279,088

Europe (non-G5) 255,503

U.S.A. 165,172

India, Taiwan, S. Korea 148,977

Middle East* 111,788

Germany* 80,943

France 80,349

Australia* / New Zealand 66,347

U.K. 60,473

Italy* 56,147

Turkey* 51,567

Spain 44,896

Latin Am 40,710

Canada 25,782

International Demand Accounts for 90% of Global IVF

# IVF Cycles Annually

Brazil, LatAm, Russia, Turkey, UAE growing 30-40%

Japan

U.S.A.

Aus NZ

Middle East

India, Tai, S.K.

Rest of Europe

Spain

* Donor restriction

7

8

Fertility and IVF Success Decline with Age

Older eggs lack energy or

mitochondria

• Energy is key to egg quality

• Egg quality declines with age

CDC 2009 report on Assisted Reproductive Technology, http://www.cdc.gov/art

9

Adding Mitochondria Increases IVF Success

Mitochondria Studies

No. of Cycles

Pregnancies Success

Rate

Huang(1) 9 4 44%

Cohen(2)* 30 13 43%

Tzeng(3) 71 25 35%

Levron(4) 15 5 33%

Lanzendorf(5)* 4 1 25%

(1) Huang et al., 1999. (2) Cohen et al., 1997, 1998; Brenner et al., 2000; Barritt et al., 2000, 2001. (3) Tzeng et al., 2004. (4) Levron et al. (5) Lanzendorf et al., 1999. * Studies conducted in the U.S.

Women who failed 2+ IVF cycles

Previous IVF success

rate = 0%

OVARIAN HYPERSTIMULATION

Hormone injections

EGG RETRIEVAL

EGG FERTILIZATION by ICSI EGG FERTILIZATION by ICSI

+ EggPC MITOCHONDRIA

EMBRYO CULTURE & TRANSFER

Current IVF Cycle IVF Cycle with AUGMENTSM

SUITABILITY

Blood tests, age, past medical history

OVARIAN HYPERSTIMULATION

Hormone injections

EGG RETRIEVAL

SUITABILITY

Blood tests, age, past medical history OVARIAN TISSUE BIOPSY

AUGMENT: Adding a Women’s Own EggPC Mitochondria to Improve Egg Quality

10

2 t

o 3

cycl

es

on a

vg.

EMBRYO CULTURE & TRANSFER

11

AUGMENTSM: Proprietary Process Developed to Improve Egg Quality

EggPC Identification and Isolation Using OvaScience Technology

Ovarian Tissue Cryopreserved

Mitochondria from EggPC Isolated/Cryopreserved

EggPC Mitochondria Injected into Woman’s Own Egg during ICSI

EggPC Bank

AUGMENTSM

(Autologous Germline Mitochondrial Energy Transfer)

Proprietary to OvaScience

ICSI: Intracytoplasmic Sperm Injection.

AUGMENT Process is Validated for International IVF Clinics

FACS Isolation of DDX4+ EggPCs

Gene2

Gene1

Gene2

6 60 600 6K 60K 600K

FACS sorting of human DDX4+ EggPCs

Real time PCR is used to quantitate number of mitochondria used for AUGMENT

O x P h o s A T P P r o d u c t io n

0 1 0 2 0 3 0

0

2 0

4 0

6 0 S u c . + R o t.

S u c . + R o t. + O lig o .

O x P h o s

T im e (* 3 0 S e c )

AT

P p

ico

mo

les

Confidential: For Internal Purposes Only Source: International data

Commenced International AUGMENT Launch

13

2014 Goals

• Achieve at least 40 AUGMENT cycles

• Introduce in at least 4 international regions

• Generate initial revenues by year end

Progress

• Launch is underway with training at select, high-quality IVF clinics

• Optimizing manufacturing and operational efficiencies in regions

• On track to meet 2014 goals for AUGMENT

• Improving egg quality in women with too few, or no eggs 25-30% of IVF patients each year*

• Preclinical proof-of-concept established in vivo

• Additional preclinical studies underway

• On target for 2015 launch

14

OvaPrimeSM: Maturing Woman’s EggPCs in vivo

* Includes: Diminished Ovarian Reserve (DOR) of 15-17%; Polycystic Ovarian Syndrome (PCOS) up to 10%; Premature Ovarian Failure/Insufficiency (POF/POI) of 1-3% 1,2,&3

1.SART; ESHRE; ICMART; Country Registries; Latin America Registry; Israeli Ministry 2.Am Fam Physician. 2009 Sep 15;80(6):579-580 3.In 1986, Carolyn Coulam, M.D. (et al) published an article called Incidence of POF

2009

2011

2012

2014

Zhang et al.

White et al.

Zhou et al.

Zou et al.

15

OvaTureSM: EggPCs Mature into Young Healthy Eggs

1st Generation Mice

Fertilization Mature Egg EggPC

Mouse

Human 2014

preclinical

VOLUME 11 | NUMER 5 | May 2009

March 2012

16

OvaTureSM: Next Generation IVF Without Hormone Hyperstimulation

• On track to demonstrate preclinical human proof of concept in 2014

• Plan to complete preclinical studies in 2016

Goal: Improve egg quality by maturing EggPCs into fresh eggs outside the body

17

Joint Venture with Intrexon

• Combines EggPC technology with Intrexon’s industrialized synthetic biology, cell therapy and gene editing capabilities

• Revenues and R&D shared equally

OvaXon: Animal and Human Applications

Gene editing: 2013

breakthrough of the year

EggPCSM

Animal Breeding Enhanced livestock, husbandry, etc.

Genetic Diseases Prevention of inherited conditions

e.g. Huntington’s, BRCA1, mitochondrial disorders

18

OvaScience Patent Portfolio

EggPCs

Gene editing

OvaPrime

AUGMENT 2 new methods patents issued Feb. ’14 extends protection into 2032

OvaTure

Additional Patents & Filings

Leveraging IP

• Bioenergetic culture media

EggPCs

• Core Composition of Matter patent issued 2011

• Additional method

patent issued Feb. ‘14 offers additional protection for manufacturing

• OvaXon JV

• Yale collaboration in endometriosis

19

Leadership Team

Senior Management Team

Michelle Dipp, MD, PhD CEO, Co-Founder Co-Founder Alnara, Verastem, Sirtris SVP, Head CEEDD, GSK MD, PhD, Oxford University BIO Board of Directors & MassBio Advisory Board

Arthur Tzianabos, PhD Chief Scientific Officer SVP, Research and Non-clinical Development, Shire Faculty, Harvard Medical School. Principal Investigator of two labs, major focus on causes of infertility

David Stern EVP, Global Commercial Operations Head Global Business Franchise, Fertility, EMD Serono Organon Pharmaceuticals

Theresa McNeely EVP, Strategic Corporate Communications Clinical Data, Inc., Millennium Pharmaceuticals, EXACT Sciences, Pyrosequencing, Allen & Co.

Board of Directors

Richard Aldrich Chairman/Co-Founder Longwood Fund, Biogen, Vertex, Sirtris, Alnara, Verastem

Jeffrey Capello Former EVP/CFO Boston Scientific

Michelle Dipp, MD, PhD

Mary Fisher President/CEO Colorescience; Skinmedica (sold to Allergan); Acorda, Cephalon, Immunex

Marc Kozin Former President North America, L.E.K. Consulting

Stephen Kraus Bessemer Venture Partners

Thomas Malley Founder, Mossrock Capital; Founder, Janus Global Life Sciences Fund

Harald Stock, PhD Getinge Group, President and CEO of ArjoHuntleigh; Former CEO Grünenthal Group; DePuy (J&J); Roche

20

Advisors

Nina Desai, PhD, HCLD Cleveland Clinic

Ali Domar, PhD Domar Center for Mind/Body Health, Boston IVF

Michael Fakih, MD Fakih IVF, Dubai

Bart Fauser, B.C.J.M. University UMC Utrecht

James Grifo, MD, PhD New York University Fertility Center

Peter Hutt Former FDA General Counsel

Gab Kovacs, MD Monash IVF, Australia

Edward Marut, MD Fertility Centers of Illinois

Kelle Moley, MD Washington University School of Medicine

Markus Montag, PhD Ilabcomm GmbH, St. Augustin, Germany

Jason Barritt, PhD, HCLD Southern California ART Reproduction Center

Claudio Benadiva, MD, HCLD Center for Advanced Reproductive Services at the University of CT

Merle Berger, MD Harvard Medical School, BIDMC, Boston IVF

Ernesto Bosch, MD Instituto Valenciano de Infertilidad Valencia. Spain

Jason Bromer, MD Shady Grove Fertility Center

Klaus Buhler, MD, PhD President German Center for Gynaecology, Endocrinology and Reproductive Medicine

Bob Casper, MD FRCS University of Toronto, Toronto Center for Advanced Reproductive Medicine (TCART)

Scott Chappel, PhD Serono, Inc., Dyax

Philip Chenette, MD Pacific Fertility Center

Joseph Conaghan, PhD, HCLD Pacific Fertility Center

21

Advisors (Continued)

Carlos Simon, MD University of Valencia

David Sinclair, PhD Professor, Harvard Medical School Co-Founder, Sirtris (acquired by GSK)

Basil Tarlatzis, MD, PhD University Thessanloniki

Hugh Taylor, MD Yale School of Medicine

Jonathan Tilly, PhD Professor and Chair, Department of Biology, Northeastern University; Massachusetts General Hospital/Harvard Medical School

Geoffrey Trew, MD Hammersmith Hospital, Imperial College, London

Herman Tournaye, MD UZ Brussels

Michael Tucker, PhD Shady Grove Fertility

Kutluk Oktay, MD Reproductive Specialists of New York

Alan Penzias, MD Harvard Medical School, BIDMC, Boston IVF, Vice Chair American Fertility Association WHO Global Infertility Guidelines Development Group

Jared Robins, MD Northwestern University

Mitchell Rosen, MD University of California San Francisco

David Sable, MD Columbia University, Former Director of St. Barnabas

William Schoolcraft, MD Colorado Center of Reproductive Medicine

Fayek Shamma, MD IVF Michigan

Daniel Shapiro, MD Reproductive Biology Associates

22

Key Financials: OvaScience (NASDAQ: OVAS)

March 31, 2014 ($ millions)

Net Loss (includes one-time charge of $1.0M for MGH License)

$7.8

Cash Burn Q1 $6.6

Cash, Cash Equivalents, Investments $89.5

Debt $0

23

Potential Near Term Milestones

AUGMENT launch underway

Establish ACE in at least 4 regions YE 2014

Achieve at least 40 international AUGMENT cycles YE 2014

Transition to commercial centers with initial revenue 2H 2014

OvaPrime

Additional proof-of-concept in other species 2H 2014

Commercial launch 2H 2015

OvaTure

Report preclinical human proof-of-concept in vitro 2H 2014

• 90% of Market is International

Standard in vitro fertilization (IVF) fails ~70%

Mainly self pay

• Near-Term Product Launches

First launch underway

Second launch planned in 2015

• Proven Leadership

Scientific, clinical and commercial success

• Proprietary Platform

Growing patient portfolio for EggPCSM

technology

OvaScience: Developing New Fertility Treatments

24

U.S.

IVF Cycles

Rest of World

25